Pentalinon andrieuxii root extract is effective in the topical treatment of cutaneous leishmaniasis caused by leishmania mexicana

Phytotherapy Research

Volumn 28, Issue 6, 2014, Pages 909-916

  Lezama Dávila, Claudio M ^a   Pan, Li ^c   Isaac Márquez, Angelica P ^b   Terrazas, Cesar ^a   Oghumu, Steve ^a   Isaac Márquez, Ricardo ^b   Pech Dzib, My ^b   Barbi, Joseph ^e   Calomeni, Edward ^a   Parinandi, Narasimham ^d   Kinghorn, A Douglas ^c   Satoskar, Abhay R ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSIDAD AUTÓNOMA DE CAMPECHE   (Mexico)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cutaneous leishmaniasis; Leishmania mexicana; Pentalinon andreuxii roots; phytomedicinal agent

Indexed keywords

ANTIPARASITIC AGENT; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON RECEPTOR; HEXANE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PENTALINON ANDRIEUXII EXTRACT; PLANT EXTRACT; STIBOGLUCONATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA MEXICANA; MEMBRANE DAMAGE; MOUSE; NONHUMAN; PARASITE LOAD; PLANT ROOT; PROMASTIGOTE; PROTEIN EXPRESSION; SHAM PROCEDURE; SKIN LEISHMANIASIS; UPREGULATION;

APOCYNACEAE; LEISHMANIA MEXICANA; MUS; PENTALINON;

CUTANEOUS LEISHMANIASIS; LEISHMANIA MEXICANA; PENTALINON ANDREUXII ROOTS; PHYTOMEDICINAL AGENT;

ANIMALS; ANTIPARASITIC AGENTS; APOCYNACEAE; DENDRITIC CELLS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; NF-KAPPA B P50 SUBUNIT; PLANT EXTRACTS; PLANT ROOTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902275703     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5079     Document Type: Article

References (26)

1. Chan-Bacab MJ, Balanza E, Deharo E, Munoz V, Garcia RD, Pena-Rodriguez LM,. 2003. Variation of leishmanicidal activity in four populations of Urechites andrieuxii. J Ethnopharmacol 86: 243-247.
2. Chan-Bacab MJ, Pena-Rodriguez LM,. 2001. Plant natural products with leishmanicidal activity. Nat Prod Rep 18: 674-688.
3. Croft SL, Seifert K, Yardley V,. 2006. Current scenario of drug development for leishmaniasis. Indian J Med Res 123: 399-410.
4. Croft SL, Yardley V,. 2002. Chemotherapy of leishmaniasis. Curr Pharm Des 8: 319-342.
5. Cummings HE, Barbi J, Reville P, et al,. 2012. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proc Natl Acad Sci U S A 109: 1251-1256.
6. Davies CR, Kaye P, Croft SL, Sundar S,. 2003. Leishmaniasis: new approaches to disease control. BMJ 326: 377-382.
7. Estevez Y, Castillo D, Pisango MT, et al,. 2007. Evaluation of the leishmanicidal activity of plants used by Peruvian Chayahuita ethnic group. J Ethnopharmacol 114: 254-259.
8. Ghosh M, Roy K, Roy S,. 2013. Immunomodulatory effects of antileishmanial drugs. J Antimicrob Chemother. doi: 10.1093/jac/dkt262
9. Inaba K, Swiggard WJ, Steinman RM, Romani N, Schuler G, Brinster C,. 2009. Isolation of dendritic cells. Curr Protoc Immunol Chapter 3, Unit 3 7.
10. Jones DE, Ackermann MR, Wille U, Hunter CA, Scott P,. 2002. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun 70: 2151-2158.
11. Kotha SR, Piper MG, Patel RB, et al,. 2011. Phospholipase A(2) activation by poultry particulate matter is mediated through extracellular signal-regulated kinase in lung epithelial cells: regulation of interleukin-8 release. Cell Biochem Biophys. doi: 10.1007/s12013-011-9329-7
12. Kvist LP, Christensen SB, Rasmussen HB, Mejia K, Gonzalez A,. 2006. Identification and evaluation of Peruvian plants used to treat malaria and leishmaniasis. J Ethnopharmacol 106: 390-402.
13. Laguna del Estal P, Calabrese S, Zabala JA, Martin T,. 1994. Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis. Med Clin (Barc) 102: 276-277.
14. Lezama-Davila CM, Isaac-Marquez AP, Barbi J, Oghumu S, Satoskar AR,. 2007a. 17Beta-estradiol increases Leishmania mexicana killing in macrophages from DBA/2 mice by enhancing production of nitric oxide but not pro-inflammatory cytokines. Am J Trop Med Hyg 76: 1125-1127.
15. Lezama-Davila CM, Isaac-Marquez AP, Zamora-Crescencio P, et al,. 2007b. Leishmanicidal activity of Pentalinon andrieuxii. Fitoterapia 78: 255-257.
16. Mejía K, Rengifo E,. 1995. Plantas medicinales de uso popular en la Amazonía peruana. Agencia Española de Cooperaciõn Internacional: Instituto de Investigaciones de la Amazonía Peruana, Lima.
17. Pan L, Lezama-Davila CM, Isaac-Marquez AP, et al,. 2012. Sterols with antileishmanial activity isolated from the roots of Pentalinon andrieuxii. Phytochemistry 82: 128-135.
18. Pinedo PM, Rengifo E, Cerruti ST, United Nations Development Programme, International Fund for Agricultural Development, Corporaciõn Andina de Fomento. 1997. Plantas medicinales de la amazonia peruana: estudio de su uso y cultivo. Instituto de Investigacíones de la Amazonía Peruana, Iquitos, Peru.
19. Pinheiro RO, Rossi-Bergmann B,. 2007. Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice. Mem Inst Oswaldo Cruz 102: 79-82.
20. Ribeiro AL, Drummond JB, Volpini AC, Andrade AC, Passos VM,. 1999. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz J Med Biol Res 32: 297-301.
21. Sampaio RN, de Paula CD, Sampaio JH, et al,. 1997. The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev Soc Bras Med Trop 30: 457-463.
22. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P,. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 154: 5320-5330.
23. Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Krönke M,. 1992. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced 'Acidic' sphingomyelin breakdown. Cell 71: 765-776.
24. Soares DC, Pereira CG, Meireles MA, Saraiva EM,. 2007. Leishmanicidal activity of a supercritical fluid fraction obtained from Tabernaemontana catharinensis. Parasitol Int 56: 135-139.
25. Veiga JP, Rosa TT, Kimachi T, et al,. 1985. Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds. Rev Inst Med Trop Sao Paulo 27: 298-302.
26. Villegas LF, Fernandez ID, Maldonado H, et al,. 1997. Evaluation of the wound-healing activity of selected traditional medicinal plants from Peru. J Ethnopharmacol 55: 193-200.